Lymph node regression after neoadjuvant chemoradiotherapy in rectal cancer.

Area of Science:

• Oncology
• Cancer Research
• Clinical Pathology

Background:

• Lymph node metastases (LNM) are critical prognostic indicators in solid tumors and essential for cancer staging.
• Neoadjuvant therapy can potentially alter nodal status through regression induction.
• Understanding LNM regression is key to refining treatment strategies and prognostication in rectal cancer.

Purpose of the Study:

• To investigate the prevalence of lymph node regression in rectal cancer patients post-neoadjuvant therapy.
• To evaluate the prognostic role of lymph node regression on patient outcomes, including overall survival and disease-free survival.

Main Methods:

• Pooled data from four independent cohorts of rectal cancer patients (n=469) treated with chemoradiotherapy.
• Developed tiered classifications based on post-treatment nodal status (ypN) and tumor regression (Reg).
• Analyzed overall survival (OS) and disease-free survival (DFS) in relation to nodal status and regression.

Main Results:

• 31% of patients had positive post-treatment lymph nodes (ypN+).
• ypN+ patients exhibited significantly worse OS compared to ypN- patients (P=0.002).
• Node-negative patients with complete lymph node regression (20% of ypN- cohort) had significantly better DFS (P=0.009) than those without regression.

Conclusions:

• Lymph node regression is a frequent occurrence following neoadjuvant therapy in rectal cancer.
• Evidence of lymph node regression in node-negative patients is associated with improved disease-free survival.
• Lymph node regression status provides valuable prognostic information beyond nodal status alone.